Supplements

Spotlight on SMA: The urgent need for early diagnosis in spinal muscular atrophy

This supplement was developed in collaboration with Cure SMA.

 

Read Now.

The diagnosis of spinal muscular atrophy (SMA), especially Type 1, is a medical emergency, as SMA is a leading genetic cause of death in infants. In infants with SMA Type 1, the onset of irreversible denervation occurs within the first 3 months with loss of 90% of motor units occurring within 6 months of age.

This supplement examines the clinical implications of delayed diagnosis of SMA, as well as assessment tools, treatment methods, and resources that are available for physicians, patients, and caregivers to better manage this rare disease.

Read Now.

Recommended Reading

Neurologists publish consensus statement on stridor in MSA
MDedge Neurology
Baricitinib may benefit patients with Aicardi-Goutières syndrome
MDedge Neurology
CMT1A neuropathy improves with investigational drug PXT3003
MDedge Neurology
Experts address barriers to genetic screening
MDedge Neurology
Families face challenges of gene therapy
MDedge Neurology
Ataluren shows real-world benefit for nonsense mutation Duchenne muscular dystrophy
MDedge Neurology
AVXS-101 may result in long-term motor improvements in SMA
MDedge Neurology
FDA approves Givlaari for treatment of acute hepatic porphyria
MDedge Neurology
Reduction in convulsive seizure frequency is associated with improved executive function in Dravet syndrome
MDedge Neurology
Study delineates spectrum of Dravet syndrome phenotypes
MDedge Neurology